Federated Hermes Inc. Increases Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Federated Hermes Inc. boosted its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 8.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,587 shares of the medical research company’s stock after acquiring an additional 11,599 shares during the quarter. Federated Hermes Inc. owned 0.11% of NeoGenomics worth $1,978,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Arizona State Retirement System boosted its position in shares of NeoGenomics by 2.0% during the second quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock valued at $496,000 after buying an additional 708 shares during the last quarter. Crossmark Global Holdings Inc. boosted its holdings in NeoGenomics by 2.9% in the second quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock worth $409,000 after purchasing an additional 842 shares during the last quarter. Quadrant Capital Group LLC raised its stake in NeoGenomics by 22.0% during the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock valued at $79,000 after buying an additional 883 shares during the last quarter. Banque Cantonale Vaudoise lifted its holdings in shares of NeoGenomics by 6.6% during the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock valued at $251,000 after buying an additional 993 shares during the period. Finally, Louisiana State Employees Retirement System boosted its stake in shares of NeoGenomics by 1.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 64,300 shares of the medical research company’s stock worth $892,000 after buying an additional 1,200 shares during the last quarter. Institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on NEO shares. Benchmark reiterated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, July 30th. Stephens reaffirmed an “overweight” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Tuesday, July 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.89.

NeoGenomics Trading Down 1.2 %

NeoGenomics stock opened at $16.28 on Friday. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -24.67 and a beta of 1.19. The firm has a 50 day moving average of $16.05 and a 200 day moving average of $14.95. The company has a current ratio of 2.01, a quick ratio of 1.93 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The firm had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. During the same period in the prior year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, research analysts predict that NeoGenomics, Inc. will post -0.22 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.